INNOVATIONS

Description

A-Biotech (Hong Kong) Company Limited is the first biotechnology company developing gene editing based therapy in Hong Kong, which was founded in 2017 by local biomedical scientists in the Chinese University of Hong Kong. Our team has profound knowledge and documented expertise in gene editing and stem cell technology. "KI-Brilliant®" is our first launched technology, which is enabled by coupling with CRISPR/Cas9 technology. It facilitates higher efficacy of in vivo knock in and holds great potential to treat various inherited diseases. By employing this proprietary platform, we have completed the development of KI-Brilliant® Human GAPDH Knock-in kit and launched for sale in 2018. Meanwhile, we focus on targeting somatic tissues developing new generation of genetically-targeted therapy to cure lethal or deleterious inherited rare disease at "One intervention and done for lifetime". "KI-HB001" was created targeting to give lifetime cure at single intervention to Hemophilia patients, and it is pre-clinically proved to be more outstanding than current Gene Augmented Therapy (GAT) with its potential of reversing disorder in single shot, long lasting expression and highly specific with minimal toxicity. KI-HB001 is just a start and we will keep fueling our innovation and extend therapeutic development for more inherited rare disease patients.